Wockhardt share price gains 14% on DCGI approval for 2 new antibiotics

  16 January 2020

Wockhardt share price gained 14 percent intraday on January 16 after the pharma company received Indian regulatory approval for its two new antibiotics.

The Drug Controller General of India (DCGI) approved EMROK (IV) and EMROK 0 (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections, and concurrent bacteraemia.

Further reading: MoneyControl
Author(s): MoneyControl
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed